HUE038588T2 - IL-22 mikrobiális rendellenességek kezelésében történõ alkalmazásra - Google Patents

IL-22 mikrobiális rendellenességek kezelésében történõ alkalmazásra

Info

Publication number
HUE038588T2
HUE038588T2 HUE12169572A HUE12169572A HUE038588T2 HU E038588 T2 HUE038588 T2 HU E038588T2 HU E12169572 A HUE12169572 A HU E12169572A HU E12169572 A HUE12169572 A HU E12169572A HU E038588 T2 HUE038588 T2 HU E038588T2
Authority
HU
Hungary
Prior art keywords
treating microbial
microbial disorders
disorders
treating
microbial
Prior art date
Application number
HUE12169572A
Other languages
English (en)
Inventor
Alexander Abbas
Dimitry Danilenko
SAUVAGE Frederic DE
Nico Ghilardi
Zora Modrusan
Wenjun Ouyang
Patricia Valdez
Yan Zheng
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HUE038588T2 publication Critical patent/HUE038588T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE12169572A 2007-11-07 2008-11-07 IL-22 mikrobiális rendellenességek kezelésében történõ alkalmazásra HUE038588T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98617007P 2007-11-07 2007-11-07
US1362007P 2007-12-13 2007-12-13
US1562007P 2007-12-20 2007-12-20

Publications (1)

Publication Number Publication Date
HUE038588T2 true HUE038588T2 (hu) 2018-10-29

Family

ID=40551983

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12169572A HUE038588T2 (hu) 2007-11-07 2008-11-07 IL-22 mikrobiális rendellenességek kezelésében történõ alkalmazásra

Country Status (26)

Country Link
US (4) US20090202475A1 (hu)
EP (3) EP3360567A1 (hu)
JP (3) JP5985150B2 (hu)
KR (2) KR20160129099A (hu)
CN (5) CN101951945A (hu)
AU (1) AU2008323770B2 (hu)
CA (1) CA2705007A1 (hu)
CO (1) CO6280406A2 (hu)
DK (1) DK2514436T3 (hu)
ES (1) ES2662845T3 (hu)
HK (2) HK1214137A1 (hu)
HR (1) HRP20180445T1 (hu)
HU (1) HUE038588T2 (hu)
IL (2) IL205623A0 (hu)
LT (1) LT2514436T (hu)
MX (1) MX2010005108A (hu)
NO (1) NO2514436T3 (hu)
PH (1) PH12013501074A1 (hu)
PL (1) PL2514436T3 (hu)
PT (1) PT2514436T (hu)
RS (1) RS57021B1 (hu)
RU (1) RU2503460C2 (hu)
SG (2) SG10202007210RA (hu)
SI (1) SI2514436T1 (hu)
WO (1) WO2009062102A2 (hu)
ZA (1) ZA201003113B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
JP2012507723A (ja) * 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
WO2011046616A2 (en) * 2009-10-15 2011-04-21 New York University Methods for modulating bacterial infection
WO2011127344A2 (en) * 2010-04-08 2011-10-13 University Of Virginia Patent Foundation Method to detect and treat infectious or inflammatory diarrhea
CN102260343A (zh) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
EP2737905B1 (en) 2011-07-25 2019-09-11 Generon (Shanghai) Corporation Ltd. Use of g-csf dimer in preparation of medicament for treatment of neurodegenerative diseases
US11119097B2 (en) 2011-12-05 2021-09-14 The Trustees Of The University Of Pennsylvania Graphene-biomolecule bioelectronic devices
CN102559759A (zh) * 2011-12-19 2012-07-11 西安交通大学医学院第一附属医院 Hip/pap重组腺病毒及其抗溃疡性结肠炎的应用
CN103182072B (zh) 2011-12-27 2017-05-03 健能隆医药技术（上海）有限公司 白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途
KR101431324B1 (ko) * 2012-08-20 2014-08-20 성균관대학교산학협력단 ＷＫＹＭＶｍ 펩티드를 포함하는 염증성 장질환 예방 또는 치료용 약학적 조성물
US9314504B2 (en) * 2013-03-14 2016-04-19 Taipei Medical University Use of members of IL-10 cytokine family
US20160039877A1 (en) 2013-03-15 2016-02-11 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
CA2903587C (en) 2013-03-15 2021-09-28 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
EP3054978B1 (en) 2013-10-08 2019-03-06 Georgia State University Research Foundation, Inc. Compositions including il-18 and il-22 and their use in anti-viral therapies
CN103554267A (zh) * 2013-10-15 2014-02-05 山西农业大学 一种具有抗菌功能的融合蛋白及其构建方法和应用
JP5515104B1 (ja) * 2013-10-25 2014-06-11 独立行政法人農業・食品産業技術総合研究機構 抗酸菌の増殖促進剤、これを添加して培養する抗酸菌の培養方法、及び、これを含有する抗酸菌の培養用培地
WO2015070077A1 (en) * 2013-11-07 2015-05-14 Memorial Sloan-Kettering Cancer Center Methods of use for il-22 in the treatment of gastrointestinal graft vs. host disease
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
CN109180786B (zh) * 2015-11-20 2021-06-18 深圳市南山区人民医院 用于预防和治疗肠致病大肠杆菌感染的肽段
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
CA3024917A1 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. Combinations of mrnas encoding immune modulating polypeptides and uses thereof
WO2019012128A1 (en) * 2017-07-13 2019-01-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) REG3ALPHA FOR USE IN THE PROTECTION OF OXYGEN-SENSITIVE GRAM-POSITIVE BACTERIA
US20240150453A1 (en) 2021-03-09 2024-05-09 Massachusetts Institute Of Technology Methods of predicting response to anti-tnf blockade in inflammatory bowel disease
CN113304247B (zh) * 2021-04-01 2024-03-19 上海市儿科医学研究所 Reg4蛋白及其在抵抗肠炎伤寒沙门氏菌感染中的应用
CN114409758A (zh) * 2022-01-24 2022-04-29 上海市儿科医学研究所 Reg4抗菌肽治疗致病性大肠埃希菌感染的应用
CN114344451B (zh) * 2022-01-25 2023-09-26 上海市肺科医院 Reg4抗菌肽治疗铜绿假单胞菌感染性肺炎的应用

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
WO1984003506A1 (en) 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5683688A (en) 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2071483C (en) 1989-10-24 2001-04-17 Mark Matteucci Oligonucleotide analogs with novel linkages
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
EP0536299B1 (en) 1990-06-27 2001-06-06 Biogen, Inc. Surface complexed lymphotoxin
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
ATE176239T1 (de) 1990-11-21 1999-02-15 Iterex Pharma Lp Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
EP0994903B1 (en) 1997-06-24 2005-05-25 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
WO1999061617A1 (en) * 1998-05-29 1999-12-02 Human Genome Sciences, Inc. Interleukins-21 and 22
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
CA2355215A1 (en) 1998-12-28 2000-07-06 Jim Wells Identifying small organic molecule ligands for binding
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
US20030170823A1 (en) * 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
GB0024442D0 (en) * 2000-10-05 2000-11-22 Isis Innovation Genetic factors affecting the outcome of viral infections
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
MXPA04001072A (es) 2001-08-03 2005-02-17 Glycart Biotechnology Ag Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada.
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
FR2833011B1 (fr) * 2001-12-04 2004-10-29 Univ Claude Bernard Lyon Nouvelle proteine a activite inhibitrice de l'il-6
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
DE60336548D1 (de) 2002-04-09 2011-05-12 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
WO2003089575A2 (en) 2002-04-15 2003-10-30 Human Genome Sciences, Inc. Antibodies that specifically bind to tl5
CA2490280A1 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
SI2289936T1 (sl) 2002-12-16 2017-10-30 Genentech, Inc. Imunoglobulinske variante in njihove uporabe
US20040176293A1 (en) * 2002-12-18 2004-09-09 Wyeth Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
MXPA05013881A (es) * 2003-06-23 2008-02-13 Genetics Inst Llc Anticuerpos contra interleucina-22 y usos de los mismos.
AU2004262002B2 (en) * 2003-08-01 2010-03-25 Stratatech Corporation Human skin equivalents expressing exogenous polypeptides
WO2005035586A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
LT2380911T (lt) 2003-11-05 2018-07-10 Roche Glycart Ag Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
US20050277593A1 (en) * 2004-05-24 2005-12-15 Washington University Therapeutic uses of Reg protein
RU2302460C1 (ru) * 2005-11-02 2007-07-10 Институт цитологии и генетики Сибирского отделения Российской академии наук (СО РАН) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBi101-IL18, КОДИРУЮЩАЯ СИНТЕЗ ИНТЕРЛЕЙКИНА-18 ЧЕЛОВЕКА В ТРАНСГЕННЫХ РАСТЕНИЯХ
JP2009541338A (ja) * 2006-06-19 2009-11-26 ワイス Ｉｌ−２２およびｉｌ−１７の調節方法

Also Published As

Publication number Publication date
CA2705007A1 (en) 2009-05-14
JP2016117760A (ja) 2016-06-30
US20130052159A1 (en) 2013-02-28
RU2010122982A (ru) 2011-12-20
SI2514436T1 (en) 2018-04-30
WO2009062102A3 (en) 2009-09-24
PT2514436T (pt) 2018-03-21
EP2514436A2 (en) 2012-10-24
LT2514436T (lt) 2018-04-10
JP2011503102A (ja) 2011-01-27
US20210338778A1 (en) 2021-11-04
SG10202007210RA (en) 2020-08-28
HRP20180445T1 (hr) 2018-04-20
CN103142999A (zh) 2013-06-12
IL258730A (en) 2018-06-28
HK1214137A1 (zh) 2016-07-22
EP2217263A2 (en) 2010-08-18
KR20160129099A (ko) 2016-11-08
WO2009062102A2 (en) 2009-05-14
EP2514436A3 (en) 2013-01-16
IL205623A0 (en) 2010-11-30
KR20100096137A (ko) 2010-09-01
CN102172395A (zh) 2011-09-07
US20090202475A1 (en) 2009-08-13
RS57021B1 (sr) 2018-05-31
CN104888193A (zh) 2015-09-09
SG185972A1 (en) 2012-12-28
ZA201003113B (en) 2015-08-26
CN108815508A (zh) 2018-11-16
RU2503460C2 (ru) 2014-01-10
KR101867606B1 (ko) 2018-06-18
DK2514436T3 (en) 2018-03-12
HK1259102A1 (zh) 2019-11-22
AU2008323770A2 (en) 2010-12-09
AU2008323770A1 (en) 2009-05-14
AU2008323770B2 (en) 2014-08-07
JP6266486B2 (ja) 2018-01-24
MX2010005108A (es) 2010-05-27
CO6280406A2 (es) 2011-05-20
NO2514436T3 (hu) 2018-05-19
US20110280828A1 (en) 2011-11-17
CN101951945A (zh) 2011-01-19
EP3360567A1 (en) 2018-08-15
PL2514436T3 (pl) 2018-06-29
ES2662845T3 (es) 2018-04-10
EP2514436B1 (en) 2017-12-20
PH12013501074A1 (en) 2015-01-26
JP2015003924A (ja) 2015-01-08
JP5985150B2 (ja) 2016-09-06

Similar Documents

Publication Publication Date Title
HK1259102A1 (zh) 用於治療微生物病症的amp
HK1157410A1 (en) Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders
EP2124778A4 (en) DEVICES FOR TREATING THE RACHIS
EP2124777A4 (en) DEVICES FOR SPINE COLUMN TREATMENT
EP2212849A4 (en) VOLUMINOUS BLOOD TRADE
ZA200908047B (en) Adjustable grinder
EP2106814A4 (en) TREATMENT DEVICE
ZA201003237B (en) Dressing
IL205939A (en) Compounds for use in the treatment of lysosomal disorders
ZA200905879B (en) Arabinoxylo-oligosaccharides in beer
GB2467710B (en) Methods for treating social disorders
AP2011005611A0 (en) Amide compounds useful in therapy.
EP2370008A4 (en) RESTRUCTURING THE VERTEBRAL COLUMN
GB0705923D0 (en) Dressing
PT2337573E (pt) Soro de leite no tratamento de linfocitopenia
PT2481407T (pt) Compostos para utilização no tratamento de distúrbios cognitivos
HK1134032A1 (en) New combination for use in the treatment of inflammatory disorders
EP2184770A4 (en) POLISHING DEVICE
EP2121785A4 (en) SYDNONIMINES - INHIBITORS FOR SPECIFIC DOPAMINE REABSORPTION AND THEIR USE IN THE TREATMENT OF DOPAMINE-RELATED DISORDERS
GB2467860B (en) Adjustable noggings
IL207906A0 (en) Treatment for ocular-related disorders
GB0718428D0 (en) Adjustable grinder
ZA201003587B (en) N-cycloalkylmethyl-2-aminothiazole-5-carboxamides for use in plant disease control
GB0820039D0 (en) Improvements in valves
GB0714119D0 (en) Improvements in transistors